L-glutamine (Endari)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Sickle Cell Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
OM
  • To reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older
Product first approved 2023biospace.com
AE
  • Sickle cell disease
Product first approved 2022biospace.com
KW
  • Sickle cell disease
Product first approved 2022biospace.com
QA
  • Sickle cell disease
Product first approved 2022biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Sickle Cell Disease
Phase 2 (1)
Sickle Cell Disease
NCT00125788 · Emmaus Medical, Inc.
2004-03 – 2008-07 · Sickle Cell Anemia, Thalassemia
What this study did
Phase 1 (3)
Other / comorbidity
NCT04634539 · Jun Gong, MD
2021-05-13 – 2025-06-17 · Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT05106101 · Emmaus Medical, Inc.
2019-07-19 – 2022-12-30 · Diverticulosis, Colonic
What this study did
NCT03947879 · Hawaii Pacific Health
2019-05 – 2022-05 · Diabetes Mellitus, Type 2
What this study did
Phase 4 (1)
Sickle Cell Disease
NCT04684381 · Emmaus Medical, Inc.
2021-01-04 – 2021-06-30 · Sickle Cell Disease, Pharmacokinetics
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT07020754 · Ain Shams University
2025-04-01 – 2026-01-25 · Radiation Induced Oral Mucositis, Oral Mucositis, Oral Mucositis Due to Radiation
What this study did
Appears in other studies (19)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Other / comorbidity
NCT04019184 · University Hospital Muenster
2019-07-18 – 2020-05-13 · Cardiac Surgery, Acute Kidney Injury
What this study did
NCT01478126 · Meshalkin Research Institute of Pathology of Circulation
2012-01 – 2013-09 · Coronary Artery Disease
What this study did
NCT00006994 · SWOG Cancer Research Network
2001-11 – 2006-04 · Cancer-related Problem/Condition, Head and Neck Cancer, Pain
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07210450 · Mazandaran University of Medical Sciences
2023-08-15 – 2025-09-27 · Pulmonary Artery Pressure, Thalassemia, Non-transfusion Dependent Thalassemia
What this study did
Phase 2 (5)
Sickle Cell Disease
NCT01048905 · UCSF Benioff Children's Hospital Oakland
2009-03 – 2014-03 · Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
What this study did
NCT00586209 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2004-02-06 – 2009-11 · Sickle Cell Anemia, Thalassemia
What this study did
Other / comorbidity
NCT07864571 · Jun Gong, MD
2026-12 – 2028-12 · Pancreatic Cancer
What this study did
NCT01783522 · Beth Faiman
2013-02 – 2013-11 · Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
What this study did
NCT00296621 · Assistance Publique - Hôpitaux de Paris
2006-02 – 2007-11 · Muscular Dystrophy, Duchenne
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01701193 · Temple Therapeutics BV
2015-02-15 – 2016-10-20 · Pelvic Adhesions
What this study did
Phase 1 (1)
Other / comorbidity
NCT02215083 · Eastern Regional Medical Center
2014-08 – 2015-04 · Peripheral Neuropathy
What this study did
Phase 4 (2)
Sickle Cell Disease
NCT05371184 · Ain Shams University
2022-01-04 – 2024-01-07 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT00647036 · Institute of Child Health
2009-07 – 2012-05 · Surgical Infants Requiring Total Parenteral Nutrition
What this study did
Early phase / not applicable (6)
Other / comorbidity
NCT07883161 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2026-12-01 – 2027-12-31 · PDAC, Pancreas Adenocarcinoma (MSI-H)
What this study did
NCT05808010 · Shandong Provincial Hospital
2023-06-07 – 2026-04 · Chronic Atrophic Gastritis
What this study did
NCT04701463 · Azienda di Servizi alla Persona di Pavia
2020-01-15 – 2020-11-25 · Amino Acid, Body Weight Changes, Skin Manifestations, Obesity, Postmenopausal Disorder
What this study did
NCT03341169 · Yonsei University
2018-03-20 – 2019-09-28 · Aortic Valve Stenois
What this study did
NCT03180775 · Rambam Health Care Campus
2017-07-01 – 2018-05-01 · Atherosclerosis, Diet Modification, Serum; Disease
What this study did
NCT01092039 · Xigo Health LLC
2010-03 – 2011-04 · Common Cold
What this study did

Competitive landscape

This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
L-Glutamine (Endari): this drugApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2025ApprovalFDA approves Endari label changes
US, FDA · Source ↗